Redaktion

Psoriatic arthritis is a chronic inflammatory disease associated with psoriasis, and its diagnosis can be challenging owing to nonspecific symptoms, absence of reliable biomarkers, and occasional delay in skin manifestations. Herein, we report a case of psoriatic arthritis that initially presented as an acute finger inflammation mimicking infection. A 46-year-old woman developed sudden swelling and pain in the left ring finger during chemotherapy for cervical cancer. Based on the results of the physical examination, laboratory tests, and magnetic resonance imaging, pyogenic flexor tenosynovitis was suspected, and synovectomy was performed; however, bacterial and mycobacterial cultures yielded negative results. Despite the administration of antibiotics, the inflammation persisted, and she was referred to the Rheumatology Department, where she was diagnosed with reactive arthritis secondary to Chlamydia infection. Although the inflammation improved after antimicrobial therapy, the finger swelling persisted. Follow-up magnetic resonance imaging and serological testing were performed, and the patient was diagnosed of seronegative rheumatoid arthritis. Four years after onset, erythematous skin lesions appeared, and dermatological evaluation confirmed plaque psoriasis; thus, a definitive diagnosis of psoriatic arthritis was established. Disease-modifying antirheumatic drug adjustments improved symptoms, but residual 'pencil-in-cup' deformity and limited finger motion remained. This case highlights the difficulty in diagnosing psoriatic arthritis when arthritis precedes skin lesions. Clinicians should consider psoriatic arthritis in persistent or refractory arthritis and carefully monitor skin and nail changes to achieve an earlier diagnosis and prevent irreversible joint damage.Weiterlesen

Psoriasis is a skin disorder which mainly occurs as a rash, scaly areas and an itchy skin. The symptoms usually occur on the chest, elbows, and the scalp. World Health Organization (WHO) reports that about 125 million individuals in the world, that is about two to three% of the world population, live with psoriasis. Moreover, approximately 30% of psoriasis patients can have psoriatic arthritis. Psoriasis can have a detrimental effect on the quality of life of the affected people. They can also deal with several chronic diseases, such as depression, metabolic syndrome, cardiovascular diseases, such as atherosclerosis, heart attacks, and strokes. The psoriasis may develop at any age of life, but this disease is most prevalent in the ages between 20 and 30 and 50-60. Psoriasis is caused by different aspects, such as hereditary aspects, lifestyle habits of modern people, diet, use of drugs, skin trauma, stress, or abnormalities in the immune system, and hormonal fluctuations. Regrettably, the available conventional measures of determining the type of psoriasis are not always accurate with human errors. In order to overcome these problems, our study would attempt to develop a new dataset classified into seven classes of psoriasis diseases. We make use of publicly accessible data like SKIN LESION, ISIC and DEMANET. To overcome the problem of class imbalances, we will use the method of image augmentation to make the number of imageries in each class close to each other.To identify the presence of psoriasis in skin disease images, we employ transfer learning algorithms. Specifically, our proposed methodology utilizes ResNet50, InceptionResNetV2, and InceptionV3 with Adam and RMSprop optimizers for psoriasis classification. During training and validation, the ResNet50 model achieved good accuracy rates with values of 92.36, 84.59, and 83.55, respectively. The InceptionV2 model demonstrated impressive accuracy during training, validation, and testing, with values of 99.07, 96.65, and 97.20, respectively. Similarly, the InceptionV3 model achieved superior accuracy rates during training, validation, and testing, with values of 99.57, 96.82, and 98.68, respectively.When compared to all the models, InceptionV3 consistently demonstrates superior accuracy.Weiterlesen

Insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) regulate cell proliferation, differentiation, metabolic processes, and immune activities. Psoriasis is a systemic inflammatory disease with metabolic disorders as an important comorbidity in the pathogenesis of which members of the IGF family could also play a role. Therefore, we decided to evaluate the levels of members of the IGF signaling pathway in patients with psoriasis. Sixty-nine people were enrolled in our study: 34 patients with psoriasis and 35 controls. The following parameters were evaluated in serum obtained from peripheral blood: total cholesterol, triglycerides, high-density lipoprotein, fasting glucose, IGF-1, IGF-1R, IGF-2, IGF-2R, IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP6, and insulin. The levels of several parameters differed between groups. The levels of fasting glucose, insulin, IGFBP3, and IGFBP6 were higher in patients with psoriasis, while the levels of IGF-1, IGF-1R, and IGBP4 were higher in controls. The results suggested that the IGF-1 signaling pathway can be involved in the pathogenesis of psoriasis and its comorbidities, especially metabolic disorders such as insulin resistance, diabetes, and metabolic syndrome. The novelty of our study is in its comprehensive assessment of the involvement of the IGF-1 signaling pathway in the pathogenesis of psoriasis and advances the understanding of the pathogenesis of psoriasis and its comorbidities.Weiterlesen

No abstract supplied.Weiterlesen

Psoriasis is a chronic, autoinflammatory skin disease. Tumor necrosis factor-alpha inhibitors are commonly used for the treatment of moderate-to-severe psoriasis; however, paradoxical psoriatic eruptions are a well-recognized adverse effect. There are no validated guidelines to manage this. We present the case of a 48-year-old woman with severe pustular psoriasis who developed acute paradoxical reactions after her first two infusions of infliximab, requiring hospitalization. She achieved disease control after transitioning to secukinumab, an interleukin-17 inhibitor. This case highlights the importance of early monitoring for paradoxical reactions in patients with severe psoriasis after initiating tumor necrosis factor-alpha inhibitor therapy and the value of transitioning to an alternative biologic class for effective management.Weiterlesen

Psoriasis is a chronic inflammatory skin disease associated with multiple comorbidities, including erectile dysfunction (ED). Data on the sexual health of male psoriasis patients in Vietnam are limited. We investigated the prevalence and severity of ED in male psoriasis patients compared with healthy individuals and explored potential associations between ED and psoriasis-related clinical characteristics. This case-control study included 135 male psoriasis patients and 166 healthy individuals aged ≥18 years and limited to those sexually active within the last 6 months. The 5-item version of the International Index of Erectile Function (IIEF) was used to assess ED risk and severity. Psoriasis patients demonstrated a higher prevalence of ED than controls (80.7% vs. 67.5%, p=0.01), with increased risk of moderate-to-severe ED. Age, obesity, age of psoriasis onset, Dermatology Life Quality Index (DLQI), Psoriasis Area Severity Index (PASI), and genital lesions were associated with ED. Advanced age and elevated PASI scores were independent risk factors for ED (p<0.05). Hence, psoriasis is a risk factor for ED. Additionally, ED may serve as an early indicator of cardiovascular risk in male patients with psoriasis.Weiterlesen

IntroductionPsoriasis and obesity often occur together, with up to 50% of patients with psoriasis being classified as obese. This increases systemic inflammation, cardiovascular risk, and disease severity while reducing the efficacy of biologic treatments. Despite this overlap, dermatology lacks obesity-specific guidance. This review evaluates lifestyle, pharmacological (glucagon-like peptide 1 receptor agonists [GLP-1 RAs] and tirzepatide) and surgical strategies, as well as clinic-level algorithms, to inform dermatological practice.MethodsWe performed a narrative synthesis of epidemiology, randomized trials, real-world studies, and guideline recommendations. Our focus was on the pathophysiology and the efficacy of GLP-1 RAs and tirzepatide, providing a practical algorithm pathway for triage, pharmacotherapy escalation, and referral criteria to a multidisciplinary unit.ResultsAlthough there are no psoriasis-specific guidelines for obesity treatment, the strong link between the two conditions and the poorer therapeutic response observed in obese patients make addressing excess weight essential for people with psoriasis. The proposed algorithms emphasize universal lifestyle counseling and dermatology-led management for patients with a BMI (body mass index) < 35 kg/m2 and without major metabolic complications. GLP-1 RAs are considered the first-line treatment, given the available scientific evidence about their efficacy in terms of weight loss and management of comorbidities, as well as their safety profile. If weight loss with these drugs is insufficient, the next proposed treatment step is tirzepatide. Bariatric surgery, including bypass procedures, should be reserved for patients with a BMI ≥ 40 kg/m2, or with a BMI ≥ 35 kg/m2 when earlier measures have failed and/or comorbidities are not adequately controlled.ConclusionDermatologists should integrate obesity assessment and patient-centered interventions into psoriasis care. A structured, multidisciplinary approach could meaningfully enhance dermatological, metabolic, and cardiovascular outcomes in patients with psoriasis and obesity.Weiterlesen

BackgroundAlthough adalimumab has shown strong efficacy and safety in clinical trials, real-world evidence in Australian patients with moderate-to-severe chronic plaque psoriasis is limited. This study assessed adalimumab efficacy and drug survival in routine clinical practice, comparing outcomes with the Phase 3 REVEAL trial and its open-label extension.MethodsData were extracted from the Australasian Psoriasis Registry for adults meeting Pharmaceutical Benefits Scheme criteria to be prescribed adalimumab for chronic plaque psoriasis. Baseline demographics, Psoriasis Area and Severity Index (PASI) scores and treatment history between June 2006 and March 2022 were analysed. Drug survival was evaluated using Kaplan-Meier and Cox regression.ResultsA total of 306 patients were included; 59.8% had prior biologic exposure compared to 12.8% in REVEAL. The mean baseline PASI was 24.1 and at 3 months, 63.5% achieved PASI75 while 33.6% achieved PASI90. PASI90 responses remained stable through 3 years and exceeded REVEAL extension rates beyond 18 months. Median drug survival was 27.9 months; survival was 97.7%, 78.6%, 63.7% and 51.0% at 3, 9, 15 and 27 months, respectively. Male sex and achieving PASI ≤ 2 predicted longer drug survival.ConclusionsIn Australian real-world practice, adalimumab demonstrated sustained effectiveness and drug survival in patients with chronic plaque psoriasis comparable to RCTs, despite higher baseline disease severity and greater prior biologic exposure.Weiterlesen

No abstract supplied.Weiterlesen

Originaltitel: The self-management support needs of people diagnosed with psoriatic arthritis: a realist review protocol Link zur Quelle

# Schlechte Zähne bei aktiver Psoriasis Wenn die Psoriasis stärker wird, leiden oft auch die Zähne. Das hat eine neue Studie herausgefunden.[1] Die Forscher haben 128 Menschen mit Psoriasis oder Psoriasis-Arthritis untersucht. Bei fast der Hälfte der Arthritis-Patienten fanden sie Zahnfleischerkrankungen.[1] Bei Menschen mit reiner Psoriasis war es etwa ein Drittel. Die Zahnprobleme traten vor allem bei Patienten auf, deren Krankheit aktiv war.[1] Das zeigt, dass Zahnärzte und Rheumatologen enger zusammenarbeiten sollten. Wenn man zum Zahnarzt geht, ist es wichtig, auch über die Psoriasis zu sprechen. Originaltitel: Periodontal Status and Disease Activity in Psoriatic Arthritis and Psoriasis: A Cross-Sectional Study Link zur Quelle

Your query appears incomplete—it begins with a title and abstract excerpt but doesn't ask a specific question. However, based on the search results provided, I can offer key information about medicinal plants as immunomodulators: **Medicinal plants contain compounds that help regulate immune function.**[1] Researchers have identified about 150 plants with immunomodulatory properties, with the **Asteraceae plant family** being the most studied.[1] *Echinacea purpurea* is particularly well-known for strengthening immune responses.[1][2] The active compounds in these plants include **polyphenols, terpenoids, and alkaloids**.[1][2] Some specific molecules like curcumin, quercetin, and resveratrol have entered clinical trials and are sold commercially.[1] These plants work by triggering immune cells like macrophages and dendritic cells to fight infections more effectively.[2] Studies show they can help with respiratory infections, viral diseases, and overall immune function.[2] For conditions like psoriasis or psoriasis arthritis where the immune system is overactive, these immunomodulators could theoretically help regulate problematic immune responses—though targeted research on these specific conditions would be needed to confirm effectiveness. **To provide a more complete answer, could you clarify what specific information you're seeking?** Are you interested in how these plants work, specific plant recommendations, or their potential application for particular conditions? Originaltitel: Medicinal Plants and Lead Phytomolecules as Immunomodulators: An Updated Review Link zur Quelle

# Fernüberwachung bei Psoriasis und ähnlichen Erkrankungen Menschen mit Psoriasis haben ein Problem. Ihre Haut verändert sich täglich, doch der Arzt untersucht sie nur alle paar Wochen. Das reicht oft nicht, um die Veränderungen zu erfassen. Die Fernüberwachung könnte das ändern. Sie beobachtet täglich, wie es der Haut geht. Es gibt zwei Wege: Der Patient fotografiert seine Haut selbst mit dem Smartphone. Oder er trägt ein kleines Messgerät, das automatisch Daten sammelt. Das hilft auf mehrere Arten. Der Arzt erkennt früher, wenn sich etwas verschlechtert. Der Patient versteht besser, wie seine Krankheit verläuft. Und wichtig: Studien zeigen, dass Patienten sehr zufrieden mit dieser Überwachung sind. Besonders gut funktioniert die Fernüberwachung, wenn der Arzt regelmäßig mit dem Patienten spricht und der Patient Informationen über seine Krankheit erhält. Dann können auch 70 Prozent der Probleme direkt von zu Hause aus gelöst werden, ohne dass man in die Klinik fahren muss. Originaltitel: Remote monitoring in chronic immune-mediated inflammatory diseases: A systematic review of active and passive approaches Link zur Quelle

Gute Nachrichten für Menschen mit Psoriasis: **Biologische Therapien helfen nicht nur gegen die Hauterkrankung**, sondern reduzieren auch Probleme mit den Augen[1]. Das zeigt eine aktuelle Studie. Viele Menschen mit Psoriasis bekommen nämlich auch Augenbeschwerden. Die Augen werden trocken oder gereizt. Mit biologischen Therapien treten diese Probleme deutlich weniger auf. Das ist praktisch, weil man nicht extra etwas gegen die Augenbeschwerden nehmen muss. Die biologischen Medikamente wirken sozusagen doppelt. Sie behandeln die Psoriasis und helfen gleichzeitig den Augen. Wenn du biologische Therapien nimmst, solltest du also auch eine Verbesserung bei eventuellen Augenproblemen bemerken. Originaltitel: Biologic therapy is associated with reduced ocular disease in psoriasis: a real-world study - Eye Link zur Quelle

Originaltitel: Oxygen-boosted dual-section microneedle patch for enhanced drug penetration and improved photodynamic and anti-inflammatory therapy in psoriasis Link zur Quelle

Originaltitel: Keratinocyte differentiation transcription factor ZNF750 coordinates the development of epidermal immunocytes Link zur Quelle

Originaltitel: Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity - Communications Medicine Link zur Quelle

# Neue Leitlinie für Psoriasis: So wird die Therapie individueller Eine wichtige Leitlinie ist aktuell überarbeitet worden. Experten aus Deutschland und Europa haben sie neu geschrieben.[1] Die Leitlinie hilft Ärztinnen und Ärzten, die richtige Behandlung für Psoriasis-Patienten zu finden. ## Das ist neu Die Guideline berücksichtigt jetzt stärker, dass jeder Mensch anders ist. Sie schaut auf die persönliche Situation des Patienten.[1] Dazu gehört auch, welche anderen Erkrankungen jemand hat. Besonders wichtig ist das bei Psoriasisarthritis. ## Warum das hilft Die Leitlinie beschreibt, wie man Psoriasis in besonderen Fällen behandelt.[3] Das können Schwangerschaften sein oder andere chronische Krankheiten. Ärzte bekommen klare Empfehlungen, was sie beachten müssen. ## Mehr Möglichkeiten Es gibt neue Medikamente, die in die Leitlinie aufgenommen wurden.[1] Das bedeutet: Patienten haben mehr Chancen auf eine Therapie, die gut passt. Die Behandlung wird nicht einfach nach Schema ablaufen, sondern auf die Person abgestimmt. Originaltitel: S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations Link zur Quelle

# Wie häufig ist Psoriasis-Arthritis weltweit? Neue Forschung zeigt, dass etwa 112 von 100.000 Erwachsenen weltweit Psoriasis-Arthritis (PsA) haben.[1] Wissenschaftler aus Aberdeen haben dafür 30 Studien zusammengefasst und ausgewertet. Die Krankheit tritt unterschiedlich oft auf der Welt auf.[1] In Europa betrifft sie etwa doppelt so viele Menschen wie in Nordamerika. In Asien ist PsA deutlich seltener. Das zeigen die Daten der Forscher besonders deutlich. Die Experten haben zwei verschiedene Arten von Studien verglichen.[1] Zum einen gab es Untersuchungen mit zufällig ausgewählten Menschen aus der Bevölkerung. Zum anderen analysierten sie große Datenbanken von Krankenkassen und Gesundheitssystemen. Interessanterweise kamen beide Methoden zu ähnlichen Ergebnissen. Ein wichtiges Ergebnis: In manchen Regionen der Welt fehlen gute Daten über PsA.[1] Das macht es schwer, ein vollständiges Bild zu bekommen. Trotzdem können Ärzte jetzt besser einschätzen, wie verbreitet die Krankheit ist. Die Studie hilft dabei, PsA besser zu verstehen und mehr Menschen bei ihrer Diagnose und Behandlung zu unterstützen.[1] Originaltitel: Comment on: The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis: reply. Link zur Quelle

Originaltitel: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP). Link zur Quelle

Originaltitel: Exploring clusters based on ultrasound-detected inflammation in patients with psoriatic arthritis: a post-hoc analysis from the ULTIMATE trial. Link zur Quelle

Originaltitel: Bridging the Gap: Characterizing Complex Immune-Mediated Inflammatory Diseases with Cutaneous Manifestations. Link zur Quelle

Originaltitel: Microbiome and Skin Health: A Systematic Review of Nutraceutical Interventions, Disease Severity, Inflammation, and Gut Microbiota Link zur Quelle

Originaltitel: Risk of Inflammatory Dermatoses Following Covid-19 Infection: A cohort Study of 204,241 Patients | Clinical and Experimental Dermatology | Oxford Academic Link zur Quelle

**Deine Kopfhaut hat ihre eigenen Bewohner – und das ist wichtig** Auf deiner Kopfhaut leben Millionen winziger Bakterien und Pilze. Diese unsichtbaren Mitbewohner beeinflussen, wie sich deine Haut anfühlt und wie gesund deine Haare bleiben. Das ist gerade für dich mit Psoriasis interessant. Eine neue Studie hat sich 63 junge Frauen angeschaut. Die Forscher fanden heraus: Zwei Bakterien-Typen dominieren überall – Cutibacterium und Staphylococcus. Bei Pilzen ist Malassezia am häufigsten. Aber hier kommt das Spannende: Je nachdem, ob deine Kopfhaut trocken oder ölig ist, leben dort unterschiedliche Mikroben. Das Wichtigste für dich: Deine Empfindlichkeit und dein Lebensstil verändern diese Mikroben deutlich. Stress, zu wenig Schlaf und ungesunde Ernährung mit viel Zucker und Fett beeinflussen vor allem die Pilze. Eine empfindliche Kopfhaut zeigte sogar die stärksten Veränderungen. Das bedeutet konkret: Wenn du deine Kopfhaut-Pflege anpasst und auf Stress, Schlaf und Ernährung achtest, hilfst du damit auch deiner Mikroflora. Originaltitel: Scalp Microbiome Composition in Young Women: Associations with Scalp Type, Sensitivity, and Lifestyle Factors Link zur Quelle